The marketing authorisation for Riprazo has been withdrawn at the request of the marketing-authorisation holder.
Riprazo : EPAR - Summary for the public (PDF/187.23 KB)
First published: 07/05/2009
Last updated: 20/09/2012
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Novartis Europharm Ltd.
|Date of issue of marketing authorisation valid throughout the European Union||
Novartis Europharm Limited
West Sussex, RH12 5AB
17/08/2012 Riprazo - EMEA/H/C/000853 - IG/0209/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Agents acting on the renin-angiotensin system
Treatment of essential hypertension.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 201217/02/2012
European Medicines Agency recommends new contraindications and warnings for aliskiren-containing medicines17/02/2012
European Medicines Agency starts review of aliskiren-containing medicines following termination of ALTITUDE study22/12/2011
European Medicines Agency recommends new contraindication and warning for Rasilez and other aliskiren medicines19/02/2009